$2.7 B

MRTX Mkt cap, 21-Mar-2019

$12.9 M

Mirati Therapeutics Revenue FY, 2018
Mirati Therapeutics Net income (FY, 2018)-98.4 M
Mirati Therapeutics EBIT (FY, 2018)-102.6 M
Mirati Therapeutics Cash, 31-Dec-201832.7 M

Mirati Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

12.9m

R&D expense

19.8m49.0m68.5m58.1m93.9m

General and administrative expense

11.1m15.8m15.3m13.5m21.7m

Operating expense total

32.0m64.7m83.8m71.5m115.6m

EBIT

(32.0m)(39.1m)(64.7m)(83.8m)(71.5m)(102.6m)

EBIT margin, %

(794%)

Pre tax profit

(52.9m)(43.7m)(64.5m)(83.1m)

Income tax expense

(23.0k)

Net Income

(52.9m)(43.7m)(64.5m)(83.1m)(70.4m)(98.4m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

9.5m

R&D expense

5.2m7.2m7.0m8.2m11.3m14.6m18.0m18.4m16.1m14.4m15.0m19.7m

General and administrative expense

2.4m2.9m3.5m3.8m4.2m4.2m4.1m3.8m3.5m3.7m3.7m5.2m

Operating expense total

8.0m10.1m10.5m12.0m15.5m18.7m22.1m22.2m19.6m18.1m18.6m24.8m

EBIT

(8.0m)(10.1m)(10.5m)(12.0m)(15.5m)(18.7m)(22.1m)(22.2m)(19.6m)(18.1m)(18.6m)(15.3m)

EBIT margin, %

(162%)

Pre tax profit

(13.7m)(11.0m)(8.6m)

Income tax expense

Net Income

(13.7m)(11.0m)(8.6m)(11.9m)(15.4m)(18.7m)(21.9m)(22.1m)(19.4m)(17.8m)(18.3m)(14.7m)

Mirati Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.2m6.6m49.5m22.4m107.7m32.7m

Accounts Receivable

Inventories

Current Assets

64.2m32.7m125.4m59.6m155.8m226.7m

PP&E

322.0k496.0k614.0k629.0k525.0k473.0k

Total Assets

64.5m33.5m128.0m63.4m157.2m228.5m

Accounts Payable

5.2m9.8m15.0m13.6m25.8m

Short-term debt

Current Liabilities

38.7m5.4m9.8m15.0m13.6m26.1m

Long-term debt

Total Debt

Total Liabilities

38.7m26.9m

Additional Paid-in Capital

214.8m260.6m415.2m428.5m594.4m751.1m

Retained Earnings

(198.4m)(242.1m)(306.6m)(389.8m)(460.6m)(559.0m)

Total Equity

25.9m28.1m118.2m48.3m143.3m201.6m

Financial Leverage

2.5 x1.2 x1.1 x1.3 x1.1 x1.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

7.6m8.3m8.5m4.9m14.3m13.4m109.9m34.6m24.5m19.8m29.8m20.0m20.6m

Current Assets

17.0m56.0m49.2m40.3m71.2m60.9m141.0m109.9m93.0m75.5m107.9m92.3m153.1m

PP&E

427.0k275.0k479.0k524.0k667.0k693.0k639.0k601.0k558.0k537.0k638.0k618.0k484.0k

Total Assets

18.0m56.3m49.7m41.3m72.2m61.9m143.7m112.5m96.0m79.2m110.8m95.0m154.5m

Accounts Payable

6.6m4.0m5.9m5.4m5.1m7.1m9.8m10.8m13.8m13.7m11.3m11.7m15.8m

Current Liabilities

41.6m5.1m7.1m9.8m10.8m13.8m13.7m11.3m11.7m16.0m

Total Liabilities

41.6m42.7m44.8m5.6m5.1m7.2m9.8m10.9m13.8m13.7m11.6m12.0m16.7m

Additional Paid-in Capital

154.1m216.1m218.4m257.9m311.5m314.7m412.5m420.6m423.1m425.9m497.5m499.8m604.0m

Retained Earnings

(187.2m)(212.0m)(223.1m)(231.7m)(254.0m)(269.5m)(288.2m)(328.5m)(350.6m)(370.0m)(408.0m)(426.4m)(475.3m)

Total Equity

(23.6m)54.7m133.9m101.7m82.2m65.5m99.1m83.0m137.8m

Financial Leverage

-0.8 x1.1 x1.1 x1.1 x1.2 x1.2 x1.1 x1.1 x1.1 x

Mirati Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(43.7m)(64.5m)(83.1m)(70.4m)(98.4m)

Depreciation and Amortization

171.0k199.0k212.0k180.0k184.0k175.0k

Accounts Receivable

Inventories

Accounts Payable

(68.0k)4.4m5.2m(1.3m)

Cash From Operating Activities

(50.7m)(68.0m)(64.7m)(70.1m)

Purchases of PP&E

(204.0k)(386.0k)(329.0k)(196.0k)(81.0k)(122.0k)

Income Taxes Paid

35.0k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(13.7m)(11.0m)(33.3m)(11.9m)(27.4m)(46.1m)(21.9m)(44.0m)(63.4m)(17.8m)(36.2m)(14.7m)

Depreciation and Amortization

105.0k154.0k100.0k153.0k101.0k139.0k91.0k41.0k

Accounts Payable

1.3m111.0k

Cash From Operating Activities

(35.8m)(7.9m)

Purchases of PP&E

(199.0k)(320.0k)(297.0k)(296.0k)(45.0k)(63.0k)(80.0k)

Mirati Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Mirati Therapeutics Operating Metrics

FY, 2016

Patents Issued

32

Patents Pending

1
Report incorrect company information